Our version is a variation of the original Myers Cocktail infusion that is now made available via injection for those seeking the benefits of the IV Infusion cocktail in a quick, easy shot
Furthermore, IR in the liver and adipose tissue has been regarded as a crucial driver of NASH morbidity and mortality (120)
At a glance Retatrutide is an investigational weekly injection from Eli Lilly, not yet licensed in the UK It targets three hormone receptors at once GLP-1, GIP and glucagon earning it the nickname "triple G" It reduces appetite, improves blood sugar, and appears to nudge resting energy expenditure upwards Phase 2 trial participants lost an average of around 24% of body weight over 48 weeks at the top dose Side effects mirror existing GLP-1 medications: nausea, mild gut symptoms, reduced appetite Expected UK approval is 18-24 months away pending Phase 3 results and MHRA review The basics: what retatrutide is Retatrutide is an investigational weekly injection being developed by Eli Lilly for weight loss and related metabolic conditions
Constipation treatment
It is still in clinical trials but has generated significant interest due to exceptional weight loss results in early studies
Unlike most entries in this directory, The Pharmacy Hub is not a traditional compounding pharmacy with a prescriber-facing or patient-facing retail presence
